aTyr Pharma Inc ATYR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $0.54
- Day Range
- $0.50–0.57
- 52-Week Range
- $0.40–7.29
- Bid/Ask
- $0.50 / $0.59
- Shares Outstanding
- 98.05M
- Market Cap
- $49.43M
- Volume/Avg
- 797,821 / 3M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 274.67
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 58
- Website
- https://www.atyrpharma.com
Valuation
|
Metric
|
ATYR
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.92 |
Price/Sales | 274.67 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ATYR
|
|---|---|
Quick Ratio | 5.73 |
Current Ratio | 5.78 |
Interest Coverage | — |
Quick Ratio
ATYR
Profitability
|
Metric
|
ATYR
|
|---|---|
Return on Assets (Normalized) | −67.88% |
Return on Equity (Normalized) | −91.28% |
Return on Invested Capital (Normalized) | −77.95% |
Return on Assets
ATYR
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|wTW?mB | LOCK|<?V#d | $122B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|v<Yf%?G | LOCK|xz%D | $70B | |||
| argenx SE ADR
ARGX
| LOCK|gK!cn# | LOCK|RQZ | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|cHY^!l | LOCK|>gRM | $38B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|qC@Xb!V | LOCK|#zr | $36B | |||
| Moderna Inc
MRNA
| LOCK|LkpM>% | LOCK|$? | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|%q#hNdT% | LOCK|@m?@ | $25B | |||
| Incyte Corp
INCY
| LOCK|xhNKcB | LOCK|%hW | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|Sn#$gv | LOCK|vx | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|zG<mTf | LOCK|$B< | $17B |
United States